Beyond Air (XAIR) Stock Price, News & Analysis

Company Overview

Beyond Air, Inc. is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity. Beyond Air is also evaluating LungFit® PT for pulmonary tuberculosis and LungFit® C for viral and bacterial lung infections, including potential applications in acute respiratory distress syndrome. These programs position the LungFit platform as a versatile therapy that may complement or improve upon existing treatment options.

Beyond Air operates primarily in the United States and collaborates with academic and clinical research centers to advance its clinical trials. The company engages with regulatory authorities, including the U.S. Food and Drug Administration, to pursue marketing approvals and expanded indications for its nitric oxide therapies. By building strategic partnerships, Beyond Air aims to broaden access to its platform technology across diverse healthcare markets.

Founded in 2013 and headquartered in East Setauket, New York, Beyond Air is led by President and Chief Executive Officer Nicholas E. Caputo, a life sciences executive with extensive experience in medical device development and regulatory strategy. Under his leadership, the company has advanced multiple product candidates through early-stage clinical evaluation and continues to build a pipeline of inhaled gas therapies designed to improve outcomes for patients with challenging respiratory conditions.

Key Stats

• Today's Range: $6.22 to $7.00
• 50-Day Range: $5.16 to $9.90
• 52-Week Range: $5.02 to $95.60
• Volume: 15,296 shs
• Average Volume: 44,799 shs
• Market Capitalization: $4.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Hold

Beyond Air Stock Analysis - MarketRank™

Beyond Air scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Beyond Air has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Beyond Air has a consensus price target of $200.00, representing about 3,064.6% upside from its current price of $6.32.

Amount of Analyst Coverage

Beyond Air has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Beyond Air is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beyond Air is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beyond Air has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.52% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 1.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently increased by 6.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beyond Air does not currently pay a dividend.

Dividend Growth

Beyond Air does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.11

News Sentiment

Beyond Air has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Beyond Air this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for XAIR on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Beyond Air to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Beyond Air in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $224,997.00 in company stock, which represents 4.9446% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Beyond Air insiders have bought more of their company's stock than they have sold. Specifically, they have bought $224,997.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

9.99% of the stock of Beyond Air is held by insiders.

Percentage Held by Institutions

31.50% of the stock of Beyond Air is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/14/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:XAIR
• CIK: 1641631
• Web: www.beyondair.net
• Phone: (516) 665-8200
• Fax: N/A
• Employees: 70
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Beyond Air: $200.00
• High Price Target: $200.00
• Low Price Target: $200.00
• Potential Upside/Downside: +3,064.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($68.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.25 million
• Net Margins: -435.71%
• Pretax Margin: -447.12%
• Return on Equity: -364.17%
• Return on Assets: -97.43%

Debt

• Debt-to-Equity Ratio: 3.48
• Current Ratio: 3.80
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: $7.68 million
• Price / Sales: 0.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.41 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 721,000
• Free Float: 649,000
• Market Cap: $4.56 million
• Optionable: Optionable
• Beta: 0.23